Consistent with these findings, our data showed that dasatinib downregulates MMP3 and that MMP3 knockout impairs metastatic potential, suggesting dasatinib as a viable therapeutic strategy to target MMP3 in breast cancer. The gene discussed is MMP3; the disease is breast carcinoma.